💊Will INS018_055 be FDA-approved by 2030?
3
90Ṁ47
2030
48%
chance

Insilico Medicine's AI-designed drug for idiopathic pulmonary fibrosis, INS018_055, has entered Phase II clinical trials. Will it become (one of) the first AI-designed drugs to get FDA approval?

Get
Ṁ1,000
to start trading!
© Predita Markets, Inc.•Termos de Uso•Privacidade